Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in Cushing's Disease
NCT00612066Phase 2Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Apr 2007
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rosiglitazone in Cushing's disease (CD), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Apr 2007; status: terminated.
02
Drugs
rosiglitazone
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT00612066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00612066.